Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

@article{Mellado2009PhaseIT,
  title={Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer},
  author={Bego{\~n}a Mellado and A Font and Antonio Jos{\'e} Ruiz Alcaraz and Luis Miguel Ant{\'o}n Aparicio and Francisco G{\'o}mez Veiga and Joan Areal and Elena Gallardo and Naim Hannaoui and Jos{\'e} Manuel Rebollido Lorenzo and Afonso H S Sousa and Pedro Luis S{\'a}nchez Fern{\'a}ndez and Pedro Andrada Gasc{\'o}n},
  journal={British Journal of Cancer},
  year={2009},
  volume={101},
  pages={1248 - 1252}
}
Background:The low probability of curing high-risk prostate cancer (PC) with local therapy suggests the need to study modality of therapeutic approaches. To this end, a prospective phase II trial of neoadjuvant docetaxel (D) and complete androgen blockade (CAB) was carried out in high-risk PC patients. The primary end point was to detect at least 10% of pCRs after chemohormonal treatment.Methods:Patients with T1c–T2 clinical stage with prostate-specific antigen (PSA) >20 ng ml−1 and/or Gleason… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Similar Papers

Loading similar papers…